|
|
|
| 11/07/2025 08:30 |
Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S. |
| 11/05/2025 12:30 |
Financial Results for the Six-Month Period Ended September 30,2025 Reference Data |
| 11/05/2025 12:30 |
CONSOLIDATED FINANCIAL REPORT [IFRS] for the Six-Month Period Ended September 30, 2025 |
| 10/30/2025 19:00 |
Revenue of LEQEMBI (Preliminary Basis) |
| 09/24/2025 08:30 |
Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S. |
| 08/05/2025 12:30 |
FY 2025 (Ending March 31,2026) First Quarter Financial Results Reference Data |
| 08/05/2025 12:30 |
CONSOLIDATED FINANCIAL REPORT [IFRS] for the Three-Month Period Ended June 30, 2025 |
| 07/31/2025 19:00 |
Revenue of LEQEMBI (Preliminary Basis) |
| 05/16/2025 08:00 |
Notice of Convocation of the 113th Ordinary General Meeting of Shareholders (2025) |
| 05/15/2025 12:30 |
Notification Regarding Partial Amendment to the Articles of Incorporation |
| 05/15/2025 12:30 |
FY 2024 (Ended March 31,2025) Full Year Financial Results Reference Data |
| 05/15/2025 12:30 |
CONSOLIDATED FINANCIAL REPORT [IFRS] for Fiscal 2024 (Year Ended March 31, 2025) |
| 05/08/2025 15:30 |
Notice Concerning Results of Tender Offer for Share Certificates, etc., of EcoNaviSta Inc. (Securities Code: 5585) |
| 05/01/2025 19:45 |
REVENUE OF LEQEMBI (PRELIMINARY BASIS) |
| 03/14/2025 17:30 |
Notice Concerning Commencement of Tender Offer for Share Certificates, etc., of EcoNaviSta Inc. (Securities Code: 5585) |
| 03/07/2025 17:00 |
Eisai Announces Appointments of Corporate Officers |
| 03/07/2025 17:00 |
Notification Regarding Changes in Representative Corporate Officers |
| 03/07/2025 17:00 |
Notice of Nominees for Directors |
| 02/07/2025 12:30 |
FY 2024 (Ending March 31, 2025) Third Quarter Financial Results Reference Data |
| 02/07/2025 12:30 |
CONSOLIDATED FINANCIAL REPORT [IFRS] for the Nine-Month Period Ended December 31, 2024 |
|
